血栓通治疗脑梗塞有效性和安全性研究

Study on the Effectiveness and Safety of Xueshuantong in Treating Cerebral Infarction

目的研讨脑梗塞患者接受血栓通治疗的有效性与安全性。方法以我院2016年1月至2017年6月收治的120例脑梗塞患者为观察对象,按随机非盲法对其进行分组,其中Ⅰ组60例接受常规抗血小板凝集、降糖、控制颅内压及对症支持等基础措施治疗,Ⅱ组60例在上述基础治疗下使用血栓通静脉滴注,观察分析两组的临床疗效、神经功能缺损状况、Barthel指数及不良反应发生率等指标。结果Ⅱ组患者经过治疗,取得的总有效率为91.7%,相对Ⅰ组的70.0%明显提高,比较差异有统计学意义(P<0.05)。治疗前,两组接受NIHSS量表、Barthel指数评估,结果相比差异无统计学意义(P>0.05)。治疗后,Ⅱ组的NIHSS量表评分显著下降,而Barthel指数高于Ⅰ组,比较差异有统计学意义(P<0.05)。两组在观察期间均未发生严重的药物相关性不良反应。结论血栓通对脑梗塞患者的神经缺损症状有改善作用,能够提高患者的生活自理能力,且用药安全有保障。

Objective To study the efficacy and safety of thrombosis therapy in patients with cerebral infarction. Methods 120 patients with cerebral infarction were enrolled in our hospital from January 2016 to June 2017. They were grouped by random and nonblind method. 60 patients in group Ⅰ received routine antiplatelet aggregation, hypoglycemic, controlled Intracranial pressure and symptomatic support and other basic measures of treatment, group Ⅱ 60 cases in the above basic treatment using thrombosis through intravenous infusion, observation and analysis of the two groups of clinical efficacy, neurological deficits, Barthel index and the incidence of adverse reactions and other indicators. Results Patients in group Ⅱ were treated after, the total effective rate was 91.7%, Relative to group Ⅰ 70% Obviously Raise, The difference was statistically significant(P<0.05). Before and after treatment, the NIHSS scale and the Barthel index were significantly different(P>0.05). After treatment, the NIHSS score of group Ⅱ was significantly decreased, while the Barthel index was higher than that of group Ⅰ, the difference was significant(P<0.05). Conclusion Xueshuantong can improve the nerve defect symptoms in patients with cerebral infarction, improve the self-care ability of patients, and ensure the safety of medication.